Back to results
US 2026/0131028 A1Published application
Combination cancer therapy
AssigneeDelta Next-Gene, LLC
InventorsErlinda M. Gordon, Fredrick L. Hall
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of coupling antic-cancer agents and anti-cancer treatments to improve the efficacy of the overall treatment. The anti-cancer agent reduces stroma in the tumor microenvironment, in part by killing stroma producing cells such as TAFs and TAMs. Reduction of tumor stroma not only improves immune cell function, including immune cells administered in a second treatment, but also allows allowing other anti-cancer treatments to better access to tumor cells.
Claims27
A method of treating cancer in an individual, the method comprising administering to the patient:
- i) an anti-cancer agent comprising a binding peptide configured to bind one or more signature (SIG) elements of a tumor;
- and,
- ii) at least one anti-cancer treatment comprising cancer immunotherapy.
Dependencies are inferred from the claim text.